CNS depressant that may increase risk of somnolence and sedation when used concomitantly with ganaxolone.
Source: NLP:ganaxolone
Brand names: Ztalmy
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator · GABA A Receptor Positive Modulators
Route: Oral
Contraindications
4 CONTRAINDICATIONS None. None. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as ZTALMY, during pregnancy. Encourage women who are taking ZTALMY during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll-free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. Risk Summary There are no available data on ZTALMY use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. In animal studies, adverse effects on development were observed in mice (fetal malformations) and rats (neurobehavioral and growth impairment) following exposure during organogenesis (mouse) or throughout gestation and lactation (rat) at maternal exposures lower than that in human adults at the maximum recommended human dose (MRHD) of 1800 mg. In addition, neuronal death was observed in rats exposed to ganaxolone during a period of brain development that begins during the third trimester of pregnancy in humans and continues during the first few years after birth. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risks of major birth defects and miscarriage for the indicated populations are unknown. Clinical Considerations Disease-associated Maternal and/or Embryofetal Risk Epilepsy, with or without exposure to antiepileptic drugs, has been associated with several adverse outcomes during pregnancy, including preeclampsia, preterm labor, antepartum and postpartum hemorrhage, placental abruption, poor fetal growth, prematurity, fetal death, and maternal mortality. The risk of maternal or fetal injury may be greatest for patients with untreated or poorly controlled convulsive seizures. Women with epilepsy who become pregnant should not abruptly discontinue antiepileptic dru
6 interactions on record
CNS depressant that may increase risk of somnolence and sedation when used concomitantly with ganaxolone.
Source: NLP:ganaxolone
CYP3A4 inducer that decreases ganaxolone exposure and efficacy; ZTALMY dosage may need to be increased but should not exceed maximum daily dosage.
Source: NLP:ganaxolone
CYP3A4 inducer that decreases ganaxolone exposure and efficacy; ZTALMY dosage may need to be increased but should not exceed maximum daily dosage.
Source: NLP:ganaxolone
CYP3A4 inducer that decreases ganaxolone exposure and efficacy; ZTALMY dosage may need to be increased but should not exceed maximum daily dosage.
Source: NLP:ganaxolone
CYP3A4 inducer that decreases ganaxolone exposure and efficacy; ZTALMY dosage may need to be increased but should not exceed maximum daily dosage.
Source: NLP:ganaxolone
UGT inhibitor that may increase ganaxolone exposure and risk of adverse reactions; consider reduction of ZTALMY dosage when initiating valproic acid.
Source: NLP:ganaxolone